Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome

Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome

Abstract Background Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic inflammation. HMGB1 is a nuclear protein released extracellularly during proinflammatory lytic cell death or secreted by activated macrophages, NK cells, and additional cell types during infectio...

Full description

Bibliographic Details
Main Authors: Karin Palmblad, Hanna Schierbeck, Erik Sundberg, Anna-Carin Horne, Helena Erlandsson Harris, Jan-Inge Henter, Ulf Andersson
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Molecular Medicine
Subjects:
HMGB1
Macrophage activation syndrome
HLH
FHL
Inflammation
Pathogenesis
Online Access:https://doi.org/10.1186/s10020-021-00308-0

Internet

https://doi.org/10.1186/s10020-021-00308-0

Similar Items